← Back to Clinical Trials
Recruiting NCT06755775
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Trial Parameters
Condition Diffuse Large B-Cell Lymphoma
Sponsor Ruijin Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-23
Completion 2029-07-23
Brief Summary
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form Exclusion Criteria: 1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant
Related Trials
NCT06755775
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
View Trial →
NCT06244368
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
View Trial →
NCT05377307
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
View Trial →